TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19092729
Drug: Valdecoxib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib and parecoxib (40 mg IV every 6 hours on day one postoperative)
Study: 11218929
Drug: Waterless hand
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL GAS [WATERLESS HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waterless hand preparation (HP) containing 61% ethyl alcohol, 1% CHG, and emollients
Study: 9232709
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy in health care centre
Study: 9232709
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy in day-care clinic
Study: 8358075
Drug: New flavoured
Approvals — FDA: no, EMA: no, PMDA: no
Description: New flavoured PEG solution for gut lavage
Study: 8358075
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (2‐day semi‐liquid diet, laxatives and cleansing enemas)
Study: 3313678
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) 1500 mg slow-release/day (Pentasa)
Study: 1062910
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ferrous iron daily
Study: 27376411
Drug: eCBT (exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: eCBT (exposure-based cognitive behavioural therapy)
Study: 24939817
Drug: 24h pretreatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24h pretreatment with dexamethasone (0.5 mg/kg/dose, q6h, total of six doses; n = 66)
Study: 24939817
Drug: 6h pretreatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6h pretreatment with dexamethasone (total of three doses; n = 58)
Study: 12460127
Drug: Manual-guided outpatient
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-guided outpatient treatments
Study: 9806127
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg daily, n = 23)
Study: 9806127
Drug: L-EE (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-EE (1 tablet containing 0.05 mg + 2.5 mg, 3 times daily, n = 25)
Study: 2536211
Drug: Extruded meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Study: 2536211
Drug: Nonextruded meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Study: 31987796
Drug: Synbiotic agents
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subspecies lactis BB-12; n=55)
Study: 28099236
Drug: Perfluorohexane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluorohexane treatment (endotracheal instillation) in addition to conventional treatment.
Study: 28099236
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (anti-infection, nutritional support, antishock measures, and supportive treatment).
Study: 23521170
Drug: Topical ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketamine (0.4 ml, 20 mg)
Study: 23521170
Drug: Topical tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tramadol (0.8 ml)
Study: 23521170
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 ml saline)
Study: 22039471
Drug: Rituximab 500
Normalized name: riTUXimab 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 500 mg/m², given twice two weeks apart
Study: 17524529
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide vaccines
Study: 1119396
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin daily
Study: 1119396
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digoxin daily
Study: 1119396
Drug: Variable doses
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable doses of digoxin (0 to 0.75 mg)
Study: 25637007
Drug: Topical coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical coconut oil applications
Study: 18596389
Drug: Sorafenib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib as a single-agent therapy
Study: 18596389
Drug: Sorafenib in
Normalized name: Product containing sorafenib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib in combination with carboplatin and paclitaxel
Study: 11095456
Drug: Weekly GH
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly GH dose (natural log transformation)
Study: 11095456
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of GH injections per week
Study: 3103416
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (2 mg/kg daily of elemental zinc supplement as acetate)
Study: 30524185
Drug: Curettage plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curettage plus NCH gel (intervention group)
Study: 22012196
Drug: IVIG +
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG + prednisolone (PSL) therapy
Study: 22012196
Drug: IVIG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG therapy
Study: 9737352
Drug: Menatetrenone (MK-4)
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (MK-4) 45 mg daily for 12 months
Study: 10334139
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP); total dosage, 1,000 microg/d
Study: 2142486
Drug: Teicoplanin 400
Normalized name: Teicoplanin 400 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400 mg per day
Study: 282051
Drug: Indomethacin with
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin with diuretic or propranolol therapy
Study: 23490226
Drug: MF/F 100/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F 100/10 μg
Study: 23490226
Drug: MF/F 200/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F 200/10 μg
Study: 23490226
Drug: MF/F 400/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F 400/10 μg
Study: 23490226
Drug: MF-MDI 200
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-MDI 200 μg
Study: 23490226
Drug: MF 200
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF 200 μg via DPI
Study: 19628108
Drug: Chia seed
Normalized name: CHIA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chia seed (CS) 25 g mixed in 0.25 L water twice daily for 12 weeks
Study: 19628108
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) 25 g mixed in 0.25 L water twice daily for 12 weeks
Study: 9261749
Drug: Individual psychotherapy
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual psychotherapy and psychopharmacological treatment (study group)
Study: 7952799
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg furosemide preadsorbed onto 160 mg charcoal
Study: 7952799
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg furosemide preadsorbed onto 200 mg charcoal
Study: 7952799
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide only (reference)
Study: 24144196
Drug: levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: levomilnacipran ER 40 mg/day
Study: 24144196
Drug: levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: levomilnacipran ER 80 mg/day
Study: 21155174
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9)
Study: 21155174
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9) in HIV-infected children
Study: 16643909
Drug: Doppler assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler assessment of blood flow to the follicle and the endometrium; serum concentrations of biochemical markers such as anti‐Müllerian hormone, inhibin B, FSH, LH, and P
Study: 8857016
Drug: Elevated cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated cardiac troponin T levels (> 0.1 ng/mL)
Study: 8857016
Drug: Lower cardiac
Normalized name: Leonurus cardiaca flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cardiac troponin T levels (≤ 0.1 ng/mL)
Study: 1536246
Drug: Betamethasone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (two doses of 12 mg, 24 hours apart)
Study: 6401442
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine 10‐20 mg
Study: 31378506
Drug: Low-Intensity Extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
Study: 30439309
Drug: cf‐DNA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: cf‐DNA in sepsis group (μg/L): 1,438.0 (1,154.0, 1,576.0)
Study: 30439309
Drug: cf‐DNA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: cf‐DNA in severe sepsis group (μg/L): 2,595.0 (2,162.0, 5,198.0)
Study: 30439309
Drug: PCT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT in sepsis group (μg/L): 5.80 (3.28, 8.85)
Study: 30439309
Drug: PCT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT in severe sepsis group (μg/L): 17.53 (8.40, 29.61)
Study: 24379169
Drug: CPAP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP and a 6-month behavioral medicine intervention targeting physical activity (PA) and eating behavior (EB)
Study: 18422060
Drug: Mean corpuscular
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean corpuscular hemoglobin concentration (MCHC) in patients with hereditary spherocytosis (35.67±1.33 g/dl)
Study: 15209811
Drug: Prednisone 20
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 20 mg oral daily
Study: 9704373
Drug: 100 units
Normalized name: heparin 100 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 units of botulinum toxin type A (second injection)
Study: 20070280
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg EPs‐7630
Study: 20070280
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg EPs‐7630
Study: 20070280
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg EPs‐7630
Study: 12589167
Drug: Quadruple immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple immunosuppressive therapy (interleukin (IL)‐2 receptor antibody, tacrolimus, mycophenolate mofetil, and prednisone)
Study: 1280802
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ibuprofen plus 30 mg codeine
Study: 26303195
Drug: Fiber intake
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber intake >15 g/1000 kcal
Study: 18507656
Drug: Atropine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (5 mg intravenously)
Study: 18507656
Drug: Atropine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (administered at the time of the nadir)
Study: 18507656
Drug: Fingolimod (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (5 mg orally)
Study: 16132406
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg subcutaneously 3 times/day for a total of 7 days
Study: 11950022
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of WOMAC LK3.0 Index
Study: 10225505
Drug: Cognitive-Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavior Therapy (Trauma Treatment Protocol; TTP)
Study: 310917
Drug: Prophylactic digitalization
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic digitalization with digoxin (1 or 1.5 mg before operation, 0.25 mg daily postoperatively)
Study: 310917
Drug: Digoxin dosage
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin dosage comparison (1 mg vs. 1.5 mg)
Study: 31358243
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (15-min video-guided training, performed twice a day for 4 weeks)
Study: 29354953
Drug: Wrist‐ankle needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist‐ankle needle therapy combined with patient controlled intravenous analgesia (PCIA)
Study: 26164267
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (five different compounds)
Study: 21396901
Drug: 9 valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 valent pneumococcal conjugate vaccines (3 doses in infancy)
Study: 21396901
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose at 9 months or early in the second year of life (suggested for evaluation)
Study: 21396901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving the vaccine)
Study: 17634547
Drug: 2.5 mg/d
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/d tibolone for 14 days
Study: 1404819
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of tacrine
Study: 1404819
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d of tacrine
Study: 1404819
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of tacrine
Study: 3932677
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (Group II)
Study: 20140462
Drug: Landiolol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.125 mg/kg)
Study: 18621625
Drug: Topotecan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (2 mg per day or 2.5 mg per day fixed dose for 5 of 7 days for 2 weeks)
Study: 18621625
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 every 21 days)
Study: 12445218
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus controlled-release chlorhexidine chip (CHX)
Study: 1752060
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) co-treatment
Study: 1752060
Drug: Gonadotrophin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin treatment alone
Study: 6126901
Drug: Melperone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone (50 mg)
Study: 6126901
Drug: Melperone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone (10 mg)
Study: 24950987
Drug: Gefitinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (500 mg)
Study: 17967673
Drug: LCT propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LCT propofol 0.1 mg/kg before induction
Study: 17967673
Drug: MCT/LCT propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT/LCT propofol 0.1 mg/kg before induction
Study: 15111341
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 20 mg once-daily for 96 weeks
Study: 15111341
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 50 mg once-daily for 96 weeks
Study: 11136277
Drug: Budesonide controlled
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide controlled ileal release (CIR) capsules, 9 mg orally in fasting state
Study: 11136277
Drug: Budesonide controlled
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide controlled ileal release (CIR) capsules, 9 mg orally after a heavy breakfast
Study: 9488587
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of oltipraz weekly for 8 weeks
Study: 9488587
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of oltipraz daily for 8 weeks
Study: 7541355
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg flurbiprofen patch (n = 65)
Study: 3170993
Drug: Azelastine 1
Normalized name: AZELASTINE 137/FLUTIC 50MCG 120D NASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 1 mg twice daily
Study: 3170993
Drug: Azelastine 2
Normalized name: azelastine 2.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 2 mg twice daily
Study: 30124572
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) (16 sessions)
Study: 28209175
Drug: Strataderm® topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strataderm® topical silicone gel only
Study: 28209175
Drug: Combined Strataderm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Strataderm® topical silicone gel and pressure garment therapy
Study: 14517705
Drug: Noscapine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noscapine (oral administration)
Study: 14517705
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no noscapine treatment)
Study: 11377130
Drug: Ferrous bis-glycinate
Normalized name: ferrous bis-glycinate HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous bis-glycinate chelate (5 mg of Fe daily per kg for 28 days)
Study: 11377130
Drug: FeSO4 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (5 mg of Fe daily per kg for 28 days)
Study: 15316606
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg orally, twice daily)
Study: 9295094
Drug: Migraineurs (Cys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraineurs (Cys or Ser alleles at codon 23 of the 5-HT2C receptor gene)
Study: 31227537
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (twice a week 1‐hour aerobic and strength exercises supervised by a physiotherapist and twice a week 1‐hour Nordic or power walking)
Study: 28986667
Drug: PR oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR oxycodone/naloxone
Study: 28986667
Drug: PR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR oxycodone plus macrogol 3350
Study: 18384087
Drug: Dietary ecological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary ecological treatments for IBD
Study: 12826988
Drug: Valerian 400
Normalized name: valerian 400 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian 400 mg and 800 mg
Study: 1503379
Drug: Cefotaxime (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (3 g/day intravenously) + Rifaximin (1200 mg/day P.O.)
Study: 1503379
Drug: Cefotaxime (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (3 g/day intravenously)
Study: 6423365
Drug: Combined methimazole-lithium
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined methimazole-lithium therapy
Study: 6423365
Drug: Monotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy of methimazole
Study: 29381229
Drug: Codrituzumab exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codrituzumab exposure of ≥230 μg ml-1 and high CD16MESF level (>5.26 × 105 MESF at least)
Study: 22751603
Drug: golimumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab (both doses)
Study: 9520587
Drug: Information received
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information received through other channels (e.g., weekly magazines)
Study: 27701901
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about cognitive problems after chemotherapy with reassuring information
Study: 27701901
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about cognitive problems after chemotherapy without reassuring information